Kestra Medical Technologies, Ltd. is experiencing strong revenue growth but faces high operating losses and significant cash burn. The firm markets a wearable cardiac defibrillator, ASSURE WCD, with a lease business model, showing promising efficacy but dependent on reimbursement policies. The global cardiac arrest treatment market is projected to grow significantly, presenting opportunities for Kestra despite competition and regulatory risks.